# 04_QA_REPORT — PP-0217 Response Assessment

## 1. Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0217 |
| PP ID | PP-0217 |
| Title | Response Assessment |
| Version | 1.0.0 |
| QA Date | 2026-08-09 |
| QA Type | Gold Production QA |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

---

# 2. QA Executive Summary

PP-0217 was produced only after the Decision Batch was explicitly **Approved + Locked**.

Production was checked against:

1. the approved PP-0217 Decision Batch;
2. CORE_WORKING_RULES v1.7;
3. FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.1;
4. approved Discussion Gold reference;
5. PP Registry;
6. supplied clinical Source Materials;
7. adjacent PP ownership and boundary logic.

The required four artifacts were produced:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

---

# 3. Layer 1 — Content QA

## 3.1 Scope respected

**PASS**

The package remains centered on:

> **How is treatment response assessed in gastric cancer, and how is the assessment used to understand whether treatment is helping, controlling, or failing to control the disease?**

It does not become a generic RECIST package, imaging package, surveillance package or treatment-after-progression package.

---

## 3.2 Atomicity

**PASS**

The package answers one clinical educational question:

> **Clinical integration of treatment response.**

The package does not attempt to own:

- formal RECIST calculation;
- detailed imaging;
- surveillance;
- recurrence detection;
- treatment-specific progression management.

---

## 3.3 Completeness

**PASS**

The approved Decision Batch domains are represented:

- definition/purpose;
- longitudinal assessment;
- baseline;
- clinical + imaging integration;
- CR/PR/SD/PD;
- standardized criteria;
- neoadjuvant/perioperative setting;
- advanced/metastatic setting;
- peritoneal disease;
- stable disease;
- progression;
- measurement uncertainty;
- immunotherapy;
- treatment reassessment;
- prognosis/cure/surveillance separation;
- patient-facing interpretation;
- safety.

---

## 3.4 Internal consistency

**PASS**

No material contradiction identified between:

- CKO;
- Knowledge Passport;
- Evidence Package;
- QA Report.

---

# 4. Layer 2 — Clinical QA

## 4.1 Guideline alignment

**PASS**

The package is anchored to supplied NCCN Gastric Cancer Version 2.2026.

NCCN explicitly contains:

- treatment response assessment;
- restaging;
- post-treatment assessment after preoperative therapy;
- peritoneal-only response/restaging pathways.

---

## 4.2 Response-assessment scope

**PASS**

The package correctly distinguishes:

**Clinical Response Assessment**

from:

**Formal RECIST Assessment**

and:

**Post-treatment Imaging.**

This is the central boundary requirement for PP-0217.

---

## 4.3 RECIST boundary

**PASS**

Detailed RECIST methodology is excluded and delegated.

The package uses RECIST only at the conceptual/integration level.

---

## 4.4 Imaging boundary

**PASS**

The package discusses imaging as a component of response assessment but does not own detailed imaging methodology.

---

## 4.5 Stable Disease safety review

**PASS**

The package explicitly prevents:

> SD = treatment failure.

The wording remains context-dependent.

---

## 4.6 Progressive Disease safety review

**PASS**

The package explicitly prevents:

> PD = no remaining treatment.

The wording directs the patient toward comprehensive reassessment.

---

## 4.7 Complete Response safety review

**PASS**

The package explicitly prevents:

> CR = guaranteed cure.

---

## 4.8 Immunotherapy response safety review

**PASS**

The package acknowledges:

- immune-specific response complexity;
- iRECIST;
- pseudo-progression at high level.

Detailed algorithms are delegated.

---

## 4.9 Peritoneal disease safety review

**PASS**

The package does not reduce peritoneal disease assessment to simple lesion measurement.

It preserves the NCCN multimodal restaging concept.

---

# 5. Layer 3 — Educational QA

## 5.1 Patient-facing clarity

**PASS**

Medical terms are explained at first use.

---

## 5.2 One-concept-per-paragraph principle

**PASS**

The CKO is modular and uses independent clinical knowledge blocks.

---

## 5.3 Longitudinal explanation

**PASS**

Baseline → treatment → follow-up → comparison → interpretation → reassessment is explicitly represented.

---

## 5.4 Misconception review

**PASS**

Dedicated misconceptions include:

- no shrinkage ≠ automatic failure;
- SD ≠ automatic failure;
- PD ≠ no more treatment;
- one scan ≠ whole story;
- RECIST ≠ entire clinical response assessment;
- CR ≠ cure;
- all patients ≠ identical assessment;
- non-measurable disease ≠ unimportant disease;
- immunotherapy progression ≠ always conventional progression;
- response category ≠ automatic treatment prescription.

---

# 6. Layer 4 — Governance QA

## 6.1 Source-First audit

**PASS**

PP-specific clinical sources were searched before production.

Relevant supplied sources included:

- NCCN Gastric Cancer Version 2.2026;
- NCI Gastric Cancer Treatment PDQ;
- ESMO-ASCO 2023;
- PP Registry;
- governance documents;
- approved Gold Discussion reference.

---

## 6.2 Governance authority audit

**PASS**

The package preserves the three authority layers:

### Governance authority

CORE_WORKING_RULES.

### Structural authority

FREEZE GOLD POPULATION PACKAGE SPECIFICATION.

### Clinical evidence authority

Supplied NCCN/NCI/ESMO-ASCO/ACS materials.

---

## 6.3 User-controlled execution audit

**PASS**

PP-0217 was executed because it was explicitly requested and subsequently approved/locked.

No next PP was inferred.

---

## 6.4 Locked decision integrity

**PASS**

Production follows the approved PP-0217 Decision Batch.

No material scope redesign was introduced during production.

---

# 7. Clinical Safety Review

## Safety rule 1

**PASS**

No individualized treatment prescription.

## Safety rule 2

**PASS**

No dosing recommendations.

## Safety rule 3

**PASS**

No automatic treatment change based on response category alone.

## Safety rule 4

**PASS**

SD is not equated with failure.

## Safety rule 5

**PASS**

PD is not equated with exhaustion of treatment options.

## Safety rule 6

**PASS**

CR is not equated with guaranteed cure.

## Safety rule 7

**PASS**

RECIST is not presented as the entire clinical decision process.

## Safety rule 8

**PASS**

Immunotherapy-specific complexity is acknowledged without reproducing detailed iRECIST rules.

---

# 8. Adjacent PP Overlap Audit

## PP-0058 — RECIST

**PASS**

Foundational RECIST knowledge remains delegated.

## PP-0059 — RECIST 1.1

**PASS**

Detailed RECIST 1.1 methodology remains delegated.

## PP-0060 — Target Lesions

**PASS**

Target-lesion methodology remains delegated.

## PP-0061 — Measurable Disease

**PASS**

Formal measurable-disease criteria remain delegated.

## PP-0062 — Non-target Lesions

**PASS**

Detailed non-target methodology remains delegated.

## PP-0063–0066 — CR/PR/SD/PD

**PASS**

PP-0217 integrates these concepts at high level without replacing the dedicated foundational packages.

## PP-0067 — Response Assessment Algorithm

**PASS**

Detailed standardized algorithm remains delegated.

## PP-0068 — Follow-up Imaging

**PASS**

Detailed imaging ownership remains delegated.

## PP-0218 — RECIST-based Assessment

**PASS**

Formal RECIST assessment remains downstream.

## PP-0219 — Post-treatment Imaging

**PASS**

Detailed post-treatment imaging remains downstream.

## PP-0220 — Surveillance

**PASS**

Surveillance remains separate.

## PP-0221 — Recurrence Detection

**PASS**

Recurrence detection remains separate.

## PP-0231 — Treatment-related Toxicity and Supportive Care

**PASS**

Detailed toxicity remains delegated.

---

# 9. Evidence Traceability Audit

## CKO

**PASS**

Major clinical concepts are represented in the Evidence Package.

## Knowledge Passport

**PASS**

Primary sources and evidence classification are declared.

## Evidence Package

**PASS**

Major clinical claims are mapped to source families.

## QA Report

**PASS**

Traceability and limitations are explicitly reviewed.

---

# 10. Evidence Claim Audit

| Claim Domain | Status |
|---|---|
| Treatment response assessment in NCCN pathway | PASS |
| Restaging after preoperative therapy | PASS |
| Peritoneal-only restaging | PASS |
| RECIST conceptual role | PASS |
| Clinical assessment broader than RECIST | PASS |
| CR/PR/SD/PD integration | PASS |
| SD not automatically failure | PASS |
| PD not automatically no further options | PASS |
| Measurement error | PASS |
| Immunotherapy-specific response complexity | PASS |
| Response ≠ prognosis | PASS |
| Response ≠ cure | PASS |
| Response ≠ surveillance | PASS |

---

# 11. Source Traceability Audit

## NCCN

**PASS**

Primary disease-specific guideline anchor.

## NCI PDQ

**PASS**

Supporting disease/treatment context.

## ESMO-ASCO

**PASS**

Professional response-evaluation framework.

## PP Registry

**PASS**

Package identity and adjacent ownership.

## Governance

**PASS**

Scope and artifact structure.

---

# 12. Knowledge Graph Audit

## Foundational prerequisites

**PASS**

RECIST and response-category foundations are represented.

## Clinical integration

**PASS**

PP-0217 occupies the intended clinical integration layer.

## Downstream

**PASS**

PP-0218 and PP-0219 are represented as downstream specialized packages.

## Follow-up

**PASS**

PP-0220 and PP-0221 are kept separate.

---

# 13. Gold Depth Integrity Review

## Requirement

The Absolute Gold Depth rule requires that artifacts:

- are not compacted;
- are not shortened;
- are not summarized;
- do not collapse substantive reasoning;
- do not reduce evidence detail;
- do not reduce Knowledge Graph depth;
- do not reduce QA depth;
- do not reduce patient-facing depth.

## Result

**PASS**

The four artifacts were produced as a full Gold package.

The package preserves:

- clinical knowledge blocks;
- patient-facing explanations;
- evidence hierarchy;
- evidence matrix;
- detailed evidence notes;
- source traceability;
- Knowledge Graph;
- boundary ownership;
- misconception handling;
- clinical safety;
- cross-artifact QA.

---

# 14. Cross-artifact Consistency

| Domain | CKO | KP | EP | QA | Status |
|---|---:|---:|---:|---:|---|
| PP identity | ✓ | ✓ | ✓ | ✓ | PASS |
| Clinical question | ✓ | ✓ | ✓ | ✓ | PASS |
| Scope | ✓ | ✓ | ✓ | ✓ | PASS |
| Baseline | ✓ | ✓ | ✓ | ✓ | PASS |
| Longitudinal assessment | ✓ | ✓ | ✓ | ✓ | PASS |
| CR/PR/SD/PD | ✓ | ✓ | ✓ | ✓ | PASS |
| RECIST boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Imaging boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| Perioperative context | ✓ | ✓ | ✓ | ✓ | PASS |
| Advanced/metastatic context | ✓ | ✓ | ✓ | ✓ | PASS |
| Peritoneal context | ✓ | ✓ | ✓ | ✓ | PASS |
| Immunotherapy | ✓ | ✓ | ✓ | ✓ | PASS |
| SD safety | ✓ | ✓ | ✓ | ✓ | PASS |
| PD safety | ✓ | ✓ | ✓ | ✓ | PASS |
| Patient interpretation | ✓ | ✓ | ✓ | ✓ | PASS |
| Knowledge Graph | ✓ | ✓ | ✓ | ✓ | PASS |
| Boundary | ✓ | ✓ | ✓ | ✓ | PASS |
| QA | ✓ | ✓ | ✓ | ✓ | PASS |

---

# 15. Package Integrity

Required files:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

**PASS**

All four required artifacts are present.

---

# 16. Boundary Integrity

## Core

Clinical integration of treatment response assessment.

## Supporting

Standardized response concepts, restaging context, measurement limitations and selected immunotherapy/peritoneal contexts.

## Explicitly Excluded

Formal RECIST methodology, detailed imaging, treatment-after-progression, surveillance, recurrence detection and individualized treatment.

## Delegated-to PP

Explicit upstream/downstream ownership is declared.

**PASS**

Boundary is concise, ownership-oriented and non-duplicative.

---

# 17. Source-First Integrity

Production is grounded in supplied project Source Files.

The principal clinical anchor is NCCN Gastric Cancer Version 2.2026.

NCI PDQ and ESMO-ASCO provide complementary evidence.

PP Registry establishes the adjacent-package ownership.

No unsupported external clinical claim was introduced to replace the project evidence base.

**PASS**

---

# 18. Future Update Readiness

Review PP-0217 when:

- NCCN changes response/restaging pathways;
- RECIST or iRECIST changes;
- new immunotherapy response evidence changes interpretation;
- perioperative reassessment pathways change;
- peritoneal-disease reassessment standards change;
- new validated response-assessment methods emerge.

**PASS**

---

# 19. Final QA Decision

## Content QA

**PASS**

## Clinical QA

**PASS**

## Educational QA

**PASS**

## Governance QA

**PASS**

## Clinical Safety Review

**PASS**

## Adjacent PP Overlap Audit

**PASS**

## Evidence Traceability Audit

**PASS**

## Source-First Audit

**PASS**

## Knowledge Graph Audit

**PASS**

## Gold Depth Integrity Review

**PASS**

## Cross-artifact Consistency

**PASS**

## Package Integrity

**PASS**

---

# 20. Final Status

# PASS — GOLD — READY FOR INTEGRATION

This QA Report confirms that PP-0217 was produced according to the approved and locked Decision Batch, the locked Gold Population Package Specification, the Source-First clinical evidence rule, the adjacent-package boundary architecture and the Absolute Gold Depth requirement.
